biomed devic servic
biomed devic servic
diagnost tool
price close busi januari
takeaway
reiter growth leader top pick
last week met lead public privat held compani life
scienc tool diagnost come week feel even better
pace innov growth ahead precis medicin believ sector
outperform other healthcar given rapid pace new test discoveri
market penetr stage expect new breakthrough research
discoveri made beyond note offer latest thought
two larger compani top pick
 manag quit confid collabor good
initi start alreadi expand see upward bia street estim
rais pt last week met ceo kevin conroy cfo
jeff elliott cologuard presid mark stenhous hour came
meet confid exass new collabor impress
manag confid visibl grow busi togeth
acknowledg rep made posit impact partial
last week announc expand partnership includ
pfizer women health channel call ob/gyn view expans
deal testimoni rep genuin desir sell cologuard belief
two work togeth drive faster adopt view would
expand partnership didnt feel realli good initi deal
indic rep welcom work rep often much
experi field get rep door larger health system
under-penetrated physician work
 larg cap growth hub innov spark ton new research
clinic applic infanc year come last week pre-announc
small top line beat guid rev bracket
light street guid adj ep our/street estim view
revenue guid conserv view setup stock derisk
big pictur updat mean far result guid
estim less human sequenc less
speci sequenc variant discov genom
deciph yet indic begin
ceo franci desouza made coupl predict expect play
underpin long-term buy thesi come year expect
sequenc becom ubiquit research medicin insight gain
sequenc thousand million speci million human
genom hundr million lay foundat world nearli
diseas better understood live patient much improv
custom gener sequenc data unpreced rate scale
petabyt data gener across system record
sequenc data gener singl year refer approxim
time size entir catalogu
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
biomed devic servic
takeaway roll
growth leader top pick
last week met lead public privat held compani life
scienc tool diagnost come week feel even better
pace innov growth ahead precis medicin believ sector
outperform other healthcar given rapid pace new test discoveri
market penetr stage expect new breakthrough
research discoveri made beyond note offer
latest thought two larger compani top pick
top pick buy-rat
 manag quit confid collabor good initi
start alreadi expand see upward bia street estim
rais pt last week met ceo kevin conroy cfo
jeff elliott cologuard presid mark stenhous hour came
meet confid exass new collabor
impress manag confid visibl growth busi togeth
acknowledg rep made posit impact partial
unclear exact number rep co-promot
cologuard estim combin sale forc given expand
sale reach higher frequenc doc think solid engin place
drive patient rescreen elig patient three year last cologuard
test sinc incept screen million american order
approxim clinician estim mix consist
primari care doc obgyn provid
last week announc expand partnership includ pfizer
women health channel call ob/gyn view expans deal
testimoni rep genuin desir sell cologuard belief
two work togeth drive faster adopt view would
expand partnership didnt feel realli good initi deal
indic rep welcom work rep often much
experi field get rep door larger health
system under-penetrated physician work
consist preview deliv upsid our/street estim
tune major beat top line easili exceed our/street
expect volum grew q/q top q/q largest sequenti
quarterli growth six quarter also ad new order provid
largest quarterli addit order clinician compani histori
roll one top pick reiter buy
rate rais pt pt use
multipl revenu estim million discount back year
ep gross margin
deliv major beat highlight record number new doc order
last week pre-announc revenu y/i
us street expect revenu
y/i complet test y/i recent
revenu volum guid test complet rev/test
beat ad record new clinician
compani histori plan provid
comment relat guidanc earn call next month
updat model time pre-announc test complet
biomed devic servic
y/i q/q y/i q/q estim
season histor recal mark compani first quarter work
agre make detail clinician end
believ help drive strong volum record new addit
order clinician manag indic us alreadi make
posit impact optimist help rep move larg
health system major increment opportun
tweak sale market cologuard commerci live network tv
footbal game even sitcom addit cabl tv network channel
cnbc etc manag indic work
abl purchas media signific discount rel rate prior
begin collabor look find optim mix network
cabl tv rather duplic effort last week indic expect
begin hire team sale peopl call gi physician
never primari call point cologuard estim
alreadi order least one cologuard test count give
colonoscopi volum cologuard appreci influenc
primari care referr network expect new
sale peopl place earli
look expand cologuard label american age follow
recommend american cancer societi ac american begin colon
cancer screen age intend pursu label expans fda
cologuard begin age quantifi increment opportun
million addit american increment billion hope meet
fda sometim govern shutdown could possibl move
meet view initi clinic trial demonstr
safeti test look demonstr efficaci cologuard
patient age manag indic safeti trial requir clinic
trial peopl get cologuard colonoscopi activ
enrol trial plan supplement data patient sampl theyv
collect year peopl age receiv cologuard test off-
label physician indic theyv peopl age
receiv cologuard test label indic fals posit rate
cohort half fals posit rate old
popul optimist begin screen american age
aim keep patient year everi year goal
rescreen patient get neg result would impli new patient
age could rescreen time lifetim
look launch cologuard activ look substitut newer
specif biomark make cologuard even better name launch next-
gener cologuard test similar better level sensit aim
improv specif order reduc fals posit rate today
somewher around better manag indic
cologuard test gener posit result major fals
posit result remind posit test result follow
patient go colonoscopi potenti lose patient life
reduc number fals posit increas size pool
patient retest neg cologuard result everi year
recommend guidelin also believ substitut new marker
lower cost good believ enabl potenti exceed
gross margin time also indic want improv specif
order rais bar event anoth compani look enter colon
biomed devic servic
cancer screen market indic program requir anoth
liver cancer surveil lead exass larg liquid biopsi develop program
manag activ biomark discoveri program across type cancer
cervix uterin esophag stomach pancreat cancer look
advanc multipl liquid biopsi test area screen recurr
monitor size liquid biopsi billion indic
lead test liver cancer surveil elig high risk american
size approxim billion liver cancer kill
peopl us year new case us year
manag estim peopl recommend repeat test
earli detect liver cancer enabl physician surgic remov cancer
current standard care detect liver cancer use ultrasound
combo ultrasound protein test two clinic trial underway
one studi valid test third case-control studi
second studi prospect studi intend begin april
plan contract forg ahead estim patient
unit state end cover cologuard out-
of-pocket cost level view remark strong progress includ coverag
medicar aet ci number blue plan manag
indic number one reason physician doesnt order cologuard
perceiv notion cologuard reimburs patient
health plan exass sale forc commit correct mispercept
catalyst commerci execut rep estim
rep new coverag decis contract increas push
cologuard reorder three year ago electronic-ord target
larg health care system advanc develop liver cancer surveil
test anticip launch earli eoy ldt though regulatori
path decis remain tbd liquid biopsi test lung nodul pancreat
expand cologuard label cologuard pursu
new acquisit partnership
see upsid our/street estim model exclud
increment benefit order american age
recommend screen ac high-risk american colon cancer
anoth peopl all-in would total american time
colon cancer impact new rep new rep come
women health channel test beyond cologuard think liver
test launch eventu model also exclud acquisit
biomatrica estim biomatrica could contribut
american elig screen never
screen thu earli day penetr hope
achiev market share time
biomed devic servic
line guid bit light setup
stock look good buy
slight beat -whi revenu guid came bit light last
week pre-announc small top line beat guid rev
bracket light street guid adj ep
our/street estim view revenue guid conserv view setup
stock de-risk plan updat model follow
earn call specif guid guid sequenc
consum grow versu low-singl digit growth
array busi revenu due compani take cautiou
view consum market our/street estim unclear us
precis guid lighter array busi consum market
expect segment acceler throughout suggest slower start
ramp year goe indic expect
slightli back-end load
first lot like
top line beat albeit modest preliminari revenu
y/i vs street
record novaseq consum pull-through record novaseq placement
novaseq place vs estim
strongest instrument revenu quarter ilmn histori
drove revenu solid growth rate highlight
y/i growth consum microarray
instrument respect vs growth respect
nextseq system grew y/i nextseq consum grew
y/i see strong potenti nextseq expand clinic
benchtop system sold custom new-to-illumina
miseq miniseq iseq consum grew y/i
veriseq ce-ivd nipt volum grew y/i
nearli million direct-to-consum test order alon
perform last year rememb begin
bit worri would tough comp
manag drove growth larger dtc custom use array
like ancestri helix mani
guid mix key believ bet set appropri
guid bottom line us sequenc consum matter
growth vs modestli disappoint
overal top line guid rev vs
street specif guid low-single-digit
growth array busi total revenu well
expect updat model follow compani
earn call part result array start slower expect
slightli back-end load
biomed devic servic
array take cautiou view direct-to-consum genet
test busi earli precis reason still clear us
expect dtc array busi reacceler later driven
grow interest consum health applic instanc helix new app
mayo clinic among other like continu contribut growth
fairli recent fda-author health report also see
expand growth dtc player countri like china south korea
japan indic number account almost doubl
geographi call newer dtc compani like wegen wuxi code
other also expect continu growth leader ancestri com
particularli compani look becom relev health applic
ilmn hiseq custom purchas one novaseq
system us suggest adopt curv novaseq span
least year longer depend ilmn next major upgrad cycl
system come
quantifi hiseq custom yet
upgrad novaseq expect custom migrat
steadili next year
addit smaller hiseq custom also indic still
larg custom move entir fleet
novaseq phase rel orderli fashion
number quarter rather all-at
ilmn novaseq instal base new-to-illumina upgrad
begin ship new novaseq flow cell prime februari
prime gear toward smaller core lab prime provid
fastest run-tim lowest run cost longest read novaseq
referenc prime flow cell ideal upgrad user hiseq
indic hudsonalpha institut earli access custom
prime flow cell use prime flow cell immun profil
relat tariff china indic see impact
tariff china reiter placement come
china though declin comment revenu come
china surmis mayb bit larger also indic
tariff system discuss think would
impact believ resolut china even
without one believ impact reflect ilmn revenu guidanc
think readili achiev regardless discuss china
end tariff
alway ask competit believ keenli
tune whatev product potenti competitor may roll ie bgi
someon els believ threat meaning competit low
indic last week commit deliv best-in-class lead
accuraci continu invest innov meaning way
hundr million per year thu think unlik anoth
compani make competit inroad next sever year
biomed devic servic
big pictur updat mean far result guid
estim less human sequenc impli
million human less speci sequenc
variant discov genom deciph yet indic
begin certainli agre
name broad rang applic technolog use
cancer liquid biopsi test foundat medicin therapi
select recurr monitor possibl earli detect cancer non-
ancestri health synthet biolog work ginkgo biowork oncolog research
stratif clinic trial crispr gene edit microbiom research clinic
exom sequenc whole genom sequenc monitor ebola outbreak africa
iseq univers nebraska would add indic like carrier screen
infecti diseas research develop insignific liquid biopsi
develop grail list exhaust expect continu
innov enabl addit research clinic applic futur
estim low-singl digit percentag peg
million newli diagnos cancer patient everi year tumor sequenc
call oncolog test like guardant health foundat
medicin foundationon help oncologist patient better understand
treat diseas
call recent fda approv loxo oncolog drug larotrectnib pan-
cancer therapi base genom biomark believ approv first
mani pan-canc precis oncolog therapi come pharma compani
use clinic trial
count popul sequenc project around globe england lead
complet genom project expect growth govern
project includ franc unit state turkey israel saudi arabia singapor
qatar franc launch pilot program wg we rna-seq plan
scale genom per year time roll us project
wg genotyp million american
importantli us call genom england gel transit
program nation health system nh believ popul sequenc project
acceler gel/nh integr genom project make clinic
discoveri improv outcom patient
test rugd rare undiagnos genet diseas grow indic
condit impact birth babi
us year assum babi born/year indic
million patient live us cover rugd whole exom sequenc we
week ago price final code whole genom sequenc wg
singl genom rugd patient announc work
mayo clinic develop wg product global enabl comprehens
genom wide analysi use rugd patient
biomed devic servic
ceo franci desouza made coupl predict expect play
underpin long-term buy thesi
come year expect sequenc becom ubiquit research
medicin insight gain sequenc thousand million
speci million human genom hundr million lay
foundat world nearli diseas better understood
live patient much improv
custom gener sequenc data unpreced rate scale
petabyt data gener across system record
sequenc data gener singl year refer approxim
time size entir catalogu
call must stock reaffirm view
reap reward superb novaseq instrument launch
enabl life scienc research explor number applic new
updat sinc analyst day ad nipt
carrier screen rare undiagnos diseas babi
consum genom oncolog pop seq
estim revis least develop world alon
peopl ever sequenc develop world popul
estim genotyp world develop
popul estim cancer patient babi rare
diseas sequenc respect cost whole genom
sequenc wg drop person lower today
expect within year see path peopl sequenc
next year driven pop seq liquid biopsi studi
cancer children think sequenc
project given lead accuraci throughput cost note we could add
million count consum genotyp to-dat
envis year
earli novemb announc acquisit long-read sequenc
leader pacbio ev next year
consensu revenu pacbio premium sharehold
pacbio deal mark largest announc acquisit year
bought solexa deal ad sharehold valu
view one best acquisit all-tim pacbio deal
remain subject regulatori clearanc believ may pose challeng
given estim togeth produc
world genom inform manag confid help
fill need marketplac long-read market acknowledg
complementari ilmn domin short-read sequenc synthesi sb
biomed devic servic
